Sign in

ABVX on Nasdaq

Abivax S.A.

Abivax S.A. is a pharmaceutical preparations company, listed on Nasdaq (ABVX).1

Price unavailable

Last updated Oct 21, 2026.

Overview

-336.1MNet income, fiscal 20252

Compare with another stock.

  • TickerABVX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersI01
  • Incorporated inFrance3
  • Business address7 Bd Haussmann, Paris3
  • Filer categoryAccelerated filer, Emerging growth company3

See how the biggest companies compare on our leaderboards

United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C. 20005.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-73.8%Return on equity2
-$161.3MFree cash flow2

Financial statements

Operating income562-$246.1M in 2025+494% since 2021
-$300.0M-$200.0M-$100.0M02021: -$41.4M-$41.4M20212022: -$64.8M-$64.8M2022+57%2023: -$127.4M-$127.4M2023+96%2024: -$173.0M-$173.0M2024+36%2025: -$246.1M-$246.1M2025+42%
Net income562-$336.1M in 2025+692% since 2021
-$400.0M-$300.0M-$200.0M-$100.0M02021: -$42.5M-$42.5M20212022: -$60.7M-$60.7M2022+43%2023: -$147.7M-$147.7M2023+143%2024: -$176.2M-$176.2M2024+19%2025: -$336.1M-$336.1M2025+91%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Other operating income4.6M EUR12.4M EUR4.6M EUR
Total operating income4.6M EUR12.4M EUR4.6M EUR
Sales and marketing-5.2M EUR-6.0M EUR-6.4M EUR
Research and development-177.8M EUR-146.5M EUR-103.2M EUR
General and administrative-67.7M EUR-32.9M EUR-22.4M EUR
Total operating expenses-250.6M EUR-185.4M EUR-132.0M EUR
Operating loss-246.1M EUR-173.0M EUR-127.4M EUR
Financial expenses-111.7M EUR-17.0M EUR-27.9M EUR
Financial income27.5M EUR13.7M EUR7.5M EUR
Financial gain (loss)-84.2M EUR-3.3M EUR-20.4M EUR
Net loss before tax-330.3M EUR-176.2M EUR-147.7M EUR
Income tax-5.8M EUR0 EUR0 EUR
Net loss for the period-336.1M EUR-176.2M EUR-147.7M EUR
Weighted average number of outstanding shares used for computing basic loss per share (in shares)69.5M shares63.0M shares43.1M shares
Weighted average number of outstanding shares used for computing diluted loss per share (in shares)69.5M shares63.0M shares43.1M shares
Basic loss per share (in euro per share)-4.83 EUR-2.80 EUR-3.43 EUR
Diluted loss per share (in euro per share)-4.83 EUR-2.80 EUR-3.43 EUR

Compare Abivax S.A. with another company

Corporate structure

Abivax S.A. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Abivax S.A.

  • Abivax S.A. I0

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Abivax S.A. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents516.7M EUR2 Dec 31, 2025144.2M EUR2 Dec 31, 2024+258.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill18.4M EUR2 Dec 31, 202518.4M EUR2 Dec 31, 20240%
Intangible assets, net (excluding goodwill)6.6M EUR2 Dec 31, 20256.6M EUR2 Dec 31, 20240%

Calendar

Drug trials and FDA: coming up

  1. Dec 2026Phase 2 trial readout expected Phase 2 trial of Obefazimod in Moderately to Severely Active Crohn Disease: primary completion expected Dec 2026 (ClinicalTrials.gov NCT06456593).7

Drug trials and FDA: recently

  1. Apr 28, 2026Phase 3 trial completed Phase 3 trial of ABX464 in Ulcerative Colitis: primary completion Apr 28, 2026, no results posted yet (ClinicalTrials.gov NCT05535946).8
  2. Jun 24, 2025Phase 3 trial completed Phase 3 trial of ABX464 in Ulcerative Colitis: primary completion Jun 24, 2025, results posted Sep 10, 2026 (ClinicalTrials.gov NCT05507203).9
  3. Jun 24, 2025Phase 3 trial completed Phase 3 trial of ABX464 in Ulcerative Colitis: primary completion Jun 24, 2025, results posted Sep 10, 2026 (ClinicalTrials.gov NCT05507216).10

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

105 filings to the SEC since October 2021: 3 annual reports, 19 large holders, 83 other. The latest 20:

  1. Sep 21, 20266-K EDGAR
  2. Sep 21, 2026F-6EF EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 13, 2026SCHEDULE 13G/A EDGAR
  5. Jul 6, 2026SCHEDULE 13D/A EDGAR
  6. Jul 2, 20266-K EDGAR
  7. Jul 2, 2026424B5 EDGAR
  8. Jul 1, 2026FWP EDGAR
  9. Jun 30, 2026FWP EDGAR
  10. Jun 30, 2026424B5 EDGAR
  11. Jun 30, 2026POSASR EDGAR
  12. Jun 29, 20266-K EDGAR
  13. Jun 2, 20266-K EDGAR
  14. May 22, 20266-K EDGAR
  15. May 20, 20266-K EDGAR
  16. May 11, 2026SCHEDULE 13D/A EDGAR
  17. May 7, 20266-K EDGAR
  18. May 7, 2026424B7 EDGAR
  19. Apr 20, 20266-K EDGAR
  20. Mar 23, 202620-F EDGAR

The 105 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
TCG Crossover Management, LLC6,007,834$800.6M19.2%−473,251
Helikon Investments Ltd2,787,131$371.4M11.1%+1,773,807
Darwin Global Management, Ltd.3,621,583$348.2M9.3%+152,926
Vestal Point Capital, LP2,349,443$313.1M7.3%+849,443
Jupiter Topco LLC1,913,933$255.1M0.1%New
UBS Group AG1,844,918$245.9M0.0%−2,702,488
ADAR1 Capital Management, LLC1,804,703$240.5M11.4%+410,684
Caligan Partners LP1,557,924$207.6M10.0%+96,000
Citadel Advisors LLC1,438,352$191.7M0.1%+894,014
Morgan Stanley1,432,185$190.9M0.0%−272,773
Westfield Capital Management Co LP1,309,825$174.5M0.6%−13,113
Ra Capital Management, L.P.1,132,557$150.9M1.3%New
Norges Bank1,100,000$146.6M0.0%New
Susquehanna International Group, Llp1,053,896$140.4M0.1%+672,614
Logos Global Management LP1,024,000$136.5M5.9%+349,000
Octagon Capital Advisors LP993,000$132.3M12.1%+316,000
Bank Of America Corp /de/971,439$129.5M0.0%+235,710
Eversept Partners, LP913,880$121.8M6.6%−20,543
Goldman Sachs Group Inc792,712$105.6M0.0%+443,915
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A.765,332$102.0M5.6%−583
Cormorant Asset Management, LP675,000$90.0M4.6%−85,000
Boxer Capital Management, LLC605,000$80.6M6.1%+405,000
Balyasny Asset Management L.P.603,840$80.5M0.2%+390,151
Siren, L.L.C.576,000$76.8M1.6%New
BlackRock, Inc.574,061$76.5M0.0%+146,726

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Abivax S.A. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAbivax S.A.1
  • CIK0001956827
  • Filer statusAccelerated filer an emerging growth company; not a shell company4
  • Incorporated inFrance4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address7 Bd Haussmann, Paris, France1
  • Phone01 53 83 09 631
  • Shares outstanding78,536,412 shares as of Dec 31, 20254
  • AuditorPricewaterhouseCoopers Audit, Neuilly-sur-Seine, France PCAOB ID 1347; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceDec 16, 20221
  • Filings105 in all: 6-K (36), CORRESP (6), SCHEDULE 13D/A (6), SCHEDULE 13G/A (6), UPLOAD (6), FWP (5), 424B5 (4), 20-F (3)1
    All 30 form types

    EFFECT (3), SC 13G (3), 144 (2), DRS/A (2), DRSLTR (2), F-1/A (2), S-8 (2), SC 13G/A (2), SEC STAFF LETTER (2), 424B4 (1), 424B7 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-3 (1), F-3ASR (1), F-6 (1), F-6EF (1), POSASR (1), SC 13D (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (20-F) Mar 23, 2026

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing one ordinary share, nominal value €0.01 per shareABVXThe Nasdaq Global Market
Ordinary shares, nominal value €0.01 per shareThe Nasdaq Global Market

From the cover page of the 20-F filed Mar 23, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15